Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Treasury Shares (2023 - 2025)

Historic Treasury Shares for InMed Pharmaceuticals (INM) over the last 3 years, with Q3 2025 value amounting to $3.9 million.

  • InMed Pharmaceuticals' Treasury Shares rose 67299.74% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 67299.74%. This contributed to the annual value of $4.5 million for FY2025, which is 73435.18% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Treasury Shares of $3.9 million as of Q3 2025, which was up 67299.74% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Treasury Shares peaked at $13.2 million during Q1 2024, and registered a low of $42096.0 during Q1 2025.
  • Moreover, its 3-year median value for Treasury Shares was $544280.0 (2024), whereas its average is $2.6 million.
  • Over the last 5 years, InMed Pharmaceuticals' Treasury Shares had its largest YoY gain of 73435.18% in 2025, and its largest YoY loss of 9968.12% in 2025.
  • InMed Pharmaceuticals' Treasury Shares (Quarter) stood at $559267.0 in 2023, then crashed by 91.56% to $47176.0 in 2024, then surged by 8250.03% to $3.9 million in 2025.
  • Its Treasury Shares stands at $3.9 million for Q3 2025, versus $4.5 million for Q2 2025 and $42096.0 for Q1 2025.